Wegovy® access expanded for Medicare beneficiaries living with obesity through the Medicare GLP-1 Bridge starting July 1, 2026

Eligible Medicare patients living with obesity will have access to Wegovy® (semaglutide) injection and pill for a $50 monthly copay Wegovy® offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major CV events...